Brand Reference: Toprol-XL
| Metric | Verified Benchmark | Source |
|---|---|---|
| Metoprolol Succinate Extended-Release RxNorm Concept ID | 221124 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0720 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.20 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $7.50 / mo | 21 Zero-PHI Verified Patient Logs |
Multi-unit membrane-coated micro-pellets release metoprolol at constant zero-order kinetics over 24 hours to selectively antagonize cardiac beta-1 receptors, blunting sympathetic catecholamine chronotropy, myocardial oxygen demand, and juxtaglomerular renin release.
Classified under Zero-Order Micro-Pellet Selective Beta-1 Adrenoceptor Blocker (Rx), Metoprolol Succinate Extended-Release exhibits a $27.80/month gap between standard U.S. retail cash counters ($34.00) and verified direct-to-patient routing ($6.20) anchored to $0.0720 CMS unit cost.
Pharmacokinetic profiling of Metoprolol Succinate Extended-Release demonstrates an elimination half-life of 3–7 hours intrinsic / 24-hour zero-order pellet delivery with 50% oral systemic bioavailability; clearance proceeds via hepatic cyp2d6 o-demethylation and alpha-hydroxylation, reaching clinical onset within 2–4 hours smooth trough-to-peak curve.
Titration schedules for Metoprolol Succinate Extended-Release (25 mg ER once daily → 50 mg ER once daily → 100 mg ER once daily → 200 mg ER once daily) require excluding heart rate < 45 bpm; pr interval > 0.24 sec / high-grade av block; pheochromocytoma without prior alpha blockade; real-world patient logs highlight exercise heart-rate ceiling (19% of reports), cold hands/feet (9% of reports), vivid dreams (6% of reports) alongside a 83.70% Worth-It consensus.
Across 21 verified cash-pay logs, Metoprolol Succinate Extended-Release achieves a 83.70% Worth-It rating with out-of-pocket spend averaging $7.50/mo versus $34.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 25 mg ER once daily for Metoprolol Succinate Extended-Release; monthly out-of-pocket dropped to $5.46 compared with $34.00 retail.
Completed 10 weeks on Metoprolol Succinate Extended-Release (50 mg ER once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 100 mg ER once daily Metoprolol Succinate Extended-Release sourced via Cash Clinic ($7.19/mo cash pay without insurance prior authorization).